Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19

NCT04644185 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT04644185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 2/3
Overall status
Terminated
Start date
March 27, 2021
Completion date
February 11, 2022
Enrollment
102 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid19